CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)
South Korea flag South Korea · Delayed Price · Currency is KRW
730.00
-70.00 (-8.75%)
Jul 28, 2026, 3:30 PM KST

CMG Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Net Income
-8,383-10,0772,6956,455-388.143,051
Depreciation & Amortization
2,9073,0823,3462,5582,2842,106
Loss (Gain) From Sale of Assets
-23.2-10.2114.0922.76-0.5
Asset Writedown & Restructuring Costs
5,1655,1651,133241.9732991.25
Loss (Gain) From Sale of Investments
-1,112-1,0475,909-35.584,145-534.01
Loss (Gain) on Equity Investments
1,4391,3631,086-1,1343,807-
Stock-Based Compensation
26.940.2257.0960.2926.64439.08
Provision & Write-off of Bad Debts
1,378954.46468.4310.6-219.54213.58
Other Operating Activities
-746.374,449-5,0463,436-764.942,545
Change in Accounts Receivable
-5,580-4,357-8,212-2,864-1,463-3,185
Change in Inventory
358.52-6,987-4,677-497.72-8,857-939.47
Change in Accounts Payable
-1,774-2,4322,816-2,0496,207165.71
Change in Other Net Operating Assets
-4,036-1,164703.02-2,248-190.64-1,129
Operating Cash Flow
-10,380-11,020290.093,9384,9382,823
Operating Cash Flow Growth
---92.63%-20.24%74.88%218.39%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Capital Expenditures
-40,065-29,630-28,098-12,384-8,382-8,176
Sale of Property, Plant & Equipment
4080.94-1.5-0.5
Cash Acquisitions
----3,129--
Sale (Purchase) of Intangibles
-2,959-3,011-3,150-2,861-1,926-3,474
Investment in Securities
43,97446,449-2,616-16,8343,485-58,948
Other Investing Activities
-328.35-328.35164.73-45491.9
Investing Cash Flow
686.1713,626-55,743-28,221-10,868-70,596

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Short-Term Debt Issued
-1,500----
Long-Term Debt Issued
--56,78521,5006,000-
Total Debt Issued
58,0001,50056,78521,5006,000-
Long-Term Debt Repaid
--246.87-294.31-404.51-371.85-113.56
Net Debt Issued (Repaid)
16,2761,25356,49121,0955,628-113.56
Issuance of Common Stock
-----72,992
Common Dividends Paid
----29.28--
Other Financing Activities
-140.02-307.34292.32-0-0-
Financing Cash Flow
16,136945.7956,78321,0665,62872,878

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Foreign Exchange Rate Adjustments
41.28-17.1815.123.07-0.940.44
Miscellaneous Cash Flow Adjustments
-0-0-00-
Net Cash Flow
6,4843,5351,346-3,213-303.225,106

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Free Cash Flow
-50,445-40,650-27,808-8,446-3,444-5,352
Free Cash Flow Growth
------
Free Cash Flow Margin
-45.81%-38.63%-28.06%-8.99%-4.19%-9.13%
Free Cash Flow Per Share
-349.48-281.84-51.60-60.81-24.80-44.03
Levered Free Cash Flow
-52,367-42,983-33,0241,460--10,906
Unlevered Free Cash Flow
-51,093-41,002-31,4541,509--10,900

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Cash Interest Paid
1,1551,049870.52457.46194.75-
Cash Income Tax Paid
590.72483.4141.22687.44107.61183.95
Change in Working Capital
-11,032-14,940-9,370-7,658-4,304-5,087